| Identification | Back Directory | [Name]
GSK 2239633A | [CAS]
1240516-71-5 | [Synonyms]
GSK 2239633A
Propanamide, N-[[3-[[3-[[(5-chloro-2-thienyl)sulfonyl]amino]-4-methoxy-1H-indazol-1-yl]methyl]phenyl]methyl]-2-hydroxy-2-methyl- | [Molecular Formula]
C24H25ClN4O5S2 | [MDL Number]
MFCD30533311 | [MOL File]
1240516-71-5.mol | [Molecular Weight]
549.06 |
| Chemical Properties | Back Directory | [density ]
1.45±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:152.46(Max Conc. mg/mL);277.67(Max Conc. mM) | [form ]
Solid | [pka]
7.03±0.30(Predicted) | [color ]
White to off-white | [InChIKey]
YTEVTHHGQMUPHC-UHFFFAOYSA-N | [SMILES]
C(NCC1=CC=CC(CN2C3=C(C(OC)=CC=C3)C(NS(C3SC(Cl)=CC=3)(=O)=O)=N2)=C1)(=O)C(O)(C)C |
| Hazard Information | Back Directory | [Uses]
GSK 2239633A, is an allosteric antagonist of human CCR4. | [in vivo]
Following intravenous dosing, plasma GSK2239633A displays rapid, bi-phasic distribution and slow terminal elimination (t1/2: 13.5 hours), suggesting that GSK2239633A is a low to moderate clearance drug. Following oral dosing, blood levels of GSK2239633A reach Cmax rapidly (median tmax: 1.0-1.5 hours). Estimated GSK2239633A bioavailability is low with a maximum value determined of only 16%[1]. GSK2239633A (Compound 9) demonstrates good pharmacokinetic data in preclinical animal studies (bioavailability in rats and beagle dogs 85% and 97% respectively)[3]. | [IC 50]
[125I]-TARC-CCR4: 7.96 (pIC50) | [storage]
Store at -20°C |
|
| Company Name: |
Twochem Co.Ltd.
|
| Tel: |
021-58111628 15800915896 |
| Website: |
cn.twochem.com |
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|